Celgene oral Crohn’s drug impresses in Phase II

Posted: October 20th, 2014  |  Company/topic: Celgene
Website:
Celgene oral Crohn's drug impresses in Phase II…

Celgene’s $2.6B deal for Crohn’s drug pays off with promising PhII

Posted: October 20th, 2014  |  Company/topic: Celgene
Website:
Celgene bet big on the little-known Irish biotech Nogra Pharma when it partnered on a mid-stage drug for Crohn's disease. And today Celgene spelled out the reasons why it gambled $710 million upfront…

Celgene Participates In New Round Of Investment For Sequenta, Inc.

Posted: October 20th, 2014  |  Company/topic: Celgene
Website:
SOUTH SAN FRANCISCO, Calif. October 20, 2014 - Sequenta, Inc., a biotechnology company developing clinical diagnostics based on immune cell receptor genes, today announced an equity investment by Cel…

Déjà vu for Celgene as NICE says ‘no’ to myeloma drug Imnovid

Posted: October 15th, 2014  |  Company/topic: Celgene
Website:
The U.K.'s cost-effectiveness watchdog has recently sounded a bit like a broken record when it comes to its cancer drug rejections. The latest to get a "no-go" from the gatekeeper? Celgene's Imnovid.